Illumina investment push


Gene sequencing company Illumina has struck a $450 million (£280 million) deal to buy privately owned US firm Verinata Health, which specialises in non-invasive tests for early identification of foetal chromosomal abnormalities.

The deal follows the collapse of Roche’s $5.7 billion hostile bid for Illumina in early 2012 – which the company rejected. It also follows Illumina’s acquisition of BlueGnome, a University of Cambridge spinout that has developed a test for counting chromosomes in a cell.

Illumina will pay $350 million up front, plus up to $100 million in milestone payments.

 


Related Content

Rapid DNA sequencing cleared for the clinic

21 November 2013 Business

news image

Illumina’s ‘next-generation’ MiSeqDx platform gets US approval

Sequencing in the fast lane

25 July 2012 Premium contentFeature

news image

Phillip Broadwith gets up to speed with the latest developments in DNA sequencing technology

Most Read

US government science institute's one time police chief linked to campus meth lab

31 July 2015 News and Analysis

news image

Explosion injuring a member of the National Institute of Standards and Technology's security force uncovered methamphetamine ...

Antifreeze polymer protects cells as they thaw

29 July 2015 Research

news image

Simple synthetic polymer found to enhance cryopreservation of red blood cells by inhibiting ice crystal growth

Most Commented

(–)-Jiadifenolide

27 July 2015 Organic Matter

news image

BRSM wonders what makes a route so good it becomes the last total synthesis of a complex target

Butterfly population collapse prompts lawsuit against EPA

5 March 2015 News and Analysis

news image

US agency criticised for failing to investigate link between glyphosate and the dwindling monarch butterfly population